BRPI0606189A2 - composição, vacina e método para proteger um animal porcino de infecção por um vìrus de prrs, célula hospedeira transfectada, método para fazer um vìrus de prrs geneticamente modificado e atenuado - Google Patents

composição, vacina e método para proteger um animal porcino de infecção por um vìrus de prrs, célula hospedeira transfectada, método para fazer um vìrus de prrs geneticamente modificado e atenuado

Info

Publication number
BRPI0606189A2
BRPI0606189A2 BRPI0606189-3A BRPI0606189A BRPI0606189A2 BR PI0606189 A2 BRPI0606189 A2 BR PI0606189A2 BR PI0606189 A BRPI0606189 A BR PI0606189A BR PI0606189 A2 BRPI0606189 A2 BR PI0606189A2
Authority
BR
Brazil
Prior art keywords
prrs virus
genetically modified
vaccine
protecting
composition
Prior art date
Application number
BRPI0606189-3A
Other languages
English (en)
Inventor
Dongwan Yoo
Changhee Lee
Jay Gregory Calvert
Siao-Kun Welch
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0606189A2 publication Critical patent/BRPI0606189A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10061—Methods of inactivation or attenuation
    • C12N2770/10062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSIçãO, VACINA E MéTODO PARA PROTEGER UM ANIMAL PORCINO DE INFECçãO POR UM VìRUS DE PRRS, CéLULA HOSPEDEIRA TRANSFECTADA, MéTODO PARA FAZER UM VìRUS DE PRRS GENETICAMENTE MODIFICADO E ATENUADO. A presente invenção refere-se a um vírus de PRRS geneticamente modificado e um polinucleotídeo que o codifica. Vacinas que compreendem o vírus geneticamente modificado e os polinucleotídeos também são fornecidos.
BRPI0606189-3A 2005-02-25 2006-02-13 composição, vacina e método para proteger um animal porcino de infecção por um vìrus de prrs, célula hospedeira transfectada, método para fazer um vìrus de prrs geneticamente modificado e atenuado BRPI0606189A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65652305P 2005-02-25 2005-02-25
US73066305P 2005-10-27 2005-10-27
PCT/IB2006/000376 WO2006129139A1 (en) 2005-02-25 2006-02-13 N protein mutants of porcine reproductive and respiratory syndrome virus

Publications (1)

Publication Number Publication Date
BRPI0606189A2 true BRPI0606189A2 (pt) 2009-06-09

Family

ID=36218763

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606189-3A BRPI0606189A2 (pt) 2005-02-25 2006-02-13 composição, vacina e método para proteger um animal porcino de infecção por um vìrus de prrs, célula hospedeira transfectada, método para fazer um vìrus de prrs geneticamente modificado e atenuado

Country Status (15)

Country Link
US (3) US7544362B1 (pt)
EP (1) EP1856141A1 (pt)
JP (1) JP4320357B2 (pt)
KR (2) KR100996105B1 (pt)
CN (1) CN101128478B (pt)
AR (1) AR052392A1 (pt)
AU (1) AU2006253891B2 (pt)
BR (1) BRPI0606189A2 (pt)
CA (1) CA2599322C (pt)
MX (1) MX2007009060A (pt)
NO (1) NO20074885L (pt)
NZ (1) NZ561848A (pt)
RU (1) RU2381035C2 (pt)
TW (1) TWI366602B (pt)
WO (1) WO2006129139A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1856141A1 (en) * 2005-02-25 2007-11-21 Pfizer Products Inc. N protein mutants of porcine reproductive and respiratory syndrome virus
KR101320192B1 (ko) 2008-10-16 2013-10-30 조에티스 엘엘씨 토크 테노 바이러스(ｔｔｖ) 분리물 및 조성물
US8846388B2 (en) 2009-10-16 2014-09-30 Zoetis Llc Infectious clones of torque teno virus
UA108902C2 (uk) * 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
TWI579297B (zh) 2011-05-27 2017-04-21 華威特（北京）生物科技有限公司 用於預防豬病感染之混合疫苗
US20140286980A1 (en) 2011-06-08 2014-09-25 Zoetis Llc Infectious clones of torque teno virus
EP2720716B1 (en) * 2011-06-14 2018-03-21 Globeimmune, Inc. Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection
CN109876139A (zh) * 2012-04-24 2019-06-14 俄亥俄州国家创新基金会 用于治疗和预防猪繁殖与呼吸综合征的组合物和方法
MX2014013964A (es) * 2012-05-17 2015-03-04 Zoetis Llc Vacunacion eficaz contral el virus del sindrome reproductivo y respiratorio porcino (prrs) antes del destete.
WO2021154055A1 (ko) * 2020-01-29 2021-08-05 주식회사 바이오포아 유럽형 돼지 생식기 호흡기 증후군 바이러스의 변이주 및 이를 포함하는 백신 조성물
KR102402645B1 (ko) * 2020-01-29 2022-05-26 주식회사 바이오포아 유럽형 돼지 생식기 호흡기 증후군 바이러스의 변이주 및 이를 포함하는 백신 조성물
KR102276341B1 (ko) * 2020-01-29 2021-07-12 주식회사 바이오포아 유럽형 돼지 생식기 호흡기 증후군 바이러스의 제조 방법 및 이의 용도
CN114315984B (zh) * 2021-12-29 2023-02-03 中国农业科学院兰州兽医研究所 一种用于制备prrsv基因ii型表位缺失疫苗毒株的n蛋白表位突变标记及其应用
CN116904402A (zh) * 2023-07-11 2023-10-20 南京农业大学 一株分泌猪繁殖与呼吸综合征病毒n蛋白单克隆抗体的杂交瘤细胞及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839912A1 (en) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
NZ513289A (en) * 1998-12-22 2003-04-29 Pfizer Prod Inc Infectious cDNA clone of north american procine reproductive and respiratory syndrome (PRRS) virus and uses thereof
JP3961222B2 (ja) * 1999-03-08 2007-08-22 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Ｐｒｒｓｖワクチン
WO2002095040A1 (en) * 2001-05-21 2002-11-28 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Delections in arterivirus replicons
WO2001055353A2 (en) * 2000-01-26 2001-08-02 Boehringer Ingelheim Vetmedica Gmbh Recombinant attenuation of prrsv
JP2004534522A (ja) * 2001-03-09 2004-11-18 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング 生きた弱毒化されたｐｒｒｓウイルス株
EP1856141A1 (en) * 2005-02-25 2007-11-21 Pfizer Products Inc. N protein mutants of porcine reproductive and respiratory syndrome virus

Also Published As

Publication number Publication date
US20100136051A1 (en) 2010-06-03
KR20100090311A (ko) 2010-08-13
US20090130143A1 (en) 2009-05-21
KR20070095453A (ko) 2007-09-28
NZ561848A (en) 2010-02-26
TWI366602B (en) 2012-06-21
CN101128478A (zh) 2008-02-20
TW200641126A (en) 2006-12-01
US7544362B1 (en) 2009-06-09
EP1856141A1 (en) 2007-11-21
CN101128478B (zh) 2013-08-14
CA2599322A1 (en) 2006-12-07
JP4320357B2 (ja) 2009-08-26
RU2007131536A (ru) 2009-03-27
RU2381035C2 (ru) 2010-02-10
NO20074885L (no) 2007-11-22
MX2007009060A (es) 2007-09-11
AU2006253891A1 (en) 2006-12-07
WO2006129139A1 (en) 2006-12-07
US20090226486A1 (en) 2009-09-10
AU2006253891B2 (en) 2011-12-01
AR052392A1 (es) 2007-03-14
JP2008531006A (ja) 2008-08-14
KR100996105B1 (ko) 2010-11-22
US8128937B2 (en) 2012-03-06
CA2599322C (en) 2013-09-03

Similar Documents

Publication Publication Date Title
BRPI0715396B8 (pt) método de produção de uma composição para vacina
UY31361A1 (es) Vacunas y componentes para inhibir celulas microbianas
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
DE602006019629D1 (de) Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
AR054251A1 (es) Vacuna de toxoide de c. perfringens alfa
BRPI0720346A2 (pt) Composições de depósito (depot) injetáveis e processo de preparação dessas composições.
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
PH12013500925B1 (en) North american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
CL2011000262A1 (es) Virus de bronquitis infecciosa (bi) derivado de un virus similar a qx-bi; composicion de vacuna que comprende dicho virus; procedimiento para preparar dicho virus.
ATE404635T1 (de) Hitzeerhärtbare silikonzusammensetzung
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
CL2013001877A1 (es) Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus.
CU23608A3 (es) Vacuna para la tuberculosis ureasa deficiente con eficacia mejorada
DK1881845T3 (da) Nipah-virusvacciner
CL2011003043A1 (es) Composicion para proteger sujeto contra serotipo de virus del dengue que comprende al menos dos serotipos de virus dengue; sistema para administrar una composicion de vacuna del dengue; kit de vacuna porque comprende al menos una composicion de vacuna contra el virus del dengue.
BRPI0920622A8 (pt) vacina contra o vírus da doença equina africana
WO2009088237A3 (ko) 투명한 수지 조성물
BRPI0818718A2 (pt) Processo de preparo de uma composição de vacina compreendendo pelo menos um antígeno e pelo menos um adjuvante
DK2234645T3 (da) Peg-interferon-beta-formuleringer
BRPI0511466A (pt) agonistas peptìdicos do receptor de vasopressina
BRPI0717223A2 (pt) polipeptÍdeos hÍbridos imunogÊnicos antiobesidade e composiÇço de vacina antiobesidade compreendendo os mesmos
WO2007082734A3 (en) Influenza vaccine
WO2009077744A3 (en) Vaccines for brucellosis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements